PE20130276A1 - Formulacion de liberacion sostenida - Google Patents

Formulacion de liberacion sostenida

Info

Publication number
PE20130276A1
PE20130276A1 PE2012002488A PE2012002488A PE20130276A1 PE 20130276 A1 PE20130276 A1 PE 20130276A1 PE 2012002488 A PE2012002488 A PE 2012002488A PE 2012002488 A PE2012002488 A PE 2012002488A PE 20130276 A1 PE20130276 A1 PE 20130276A1
Authority
PE
Peru
Prior art keywords
formula
emulsion
polymer
lactic acid
sustained release
Prior art date
Application number
PE2012002488A
Other languages
English (en)
Inventor
Tomomichi Futo
Hikaru Taira
Seitaro Mizukami
Naoyuki Murata
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44583663&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130276(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20130276A1 publication Critical patent/PE20130276A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5089—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J3/00—Processes of treating or compounding macromolecular substances
    • C08J3/005—Processes for mixing polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L67/00—Compositions of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Compositions of derivatives of such polymers
    • C08L67/04—Polyesters derived from hydroxycarboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2367/00—Characterised by the use of polyesters obtained by reactions forming a carboxylic ester link in the main chain; Derivatives of such polymers
    • C08J2367/04—Polyesters derived from hydroxy carboxylic acids, e.g. lactones
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2389/00—Characterised by the use of proteins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L89/00—Compositions of proteins; Compositions of derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA FORMULACION DE LIBERACION SOSTENIDA QUE COMPRENDE A) UN COMPUESTO DERIVADO DE METASTATINA DE FORMULA (I): AC-D-TYR-HYP-ASN-THR-PHE-AZAGLY-LEU-ARG(ME)-TRP-NH2 Y B) UN POLIMERO DE ACIDO LACTICO. REFERIDO ADEMAS A UN METODO DE PREPARACION DE LA FORMULACION QUE COMPRENDE SOMETER: (1) UNA EMULSION Ag/Ac/Ag OBTENIDA AL EMULSIONAR UNA EMULSION Ag/Ac COMPUESTA POR UNA FASE ACUOSA INTERNA QUE CONTIENE EL COMPUESTO DE FORMULA (I) Y UNA FASE OLEOSA QUE CONTIENE EL POLIMERO DE ACIDO LACTICO; O (2) UNA EMULSION DE Ac/Ag OBTENIDA AL EMULSIONAR UNA FASE OLEOSA QUE CONTIENE EL COMPUESTO DE FORMULA (I) Y EL POLIMERO DE ACIDO LACTICO; A UN METODO DE SECADO EN AGUA. DICHA FORMULACION ES UTIL PARA EL TRATAMIENTO O PREVENCION DEL CANCER
PE2012002488A 2010-06-25 2011-06-23 Formulacion de liberacion sostenida PE20130276A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2010144792 2010-06-25

Publications (1)

Publication Number Publication Date
PE20130276A1 true PE20130276A1 (es) 2013-03-20

Family

ID=44583663

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012002488A PE20130276A1 (es) 2010-06-25 2011-06-23 Formulacion de liberacion sostenida

Country Status (24)

Country Link
US (2) US20130210742A1 (es)
EP (1) EP2585091B1 (es)
JP (1) JP5838173B2 (es)
KR (1) KR20130097088A (es)
CN (1) CN103025343B (es)
AR (1) AR081980A1 (es)
AU (1) AU2011270093A1 (es)
BR (1) BR112012032544A2 (es)
CA (1) CA2802209C (es)
CL (1) CL2012003645A1 (es)
CR (1) CR20120604A (es)
DO (1) DOP2012000304A (es)
EA (1) EA021663B1 (es)
EC (1) ECSP12012350A (es)
ES (1) ES2513569T3 (es)
IL (1) IL223266A0 (es)
MA (1) MA34321B1 (es)
MX (1) MX2012014265A (es)
PE (1) PE20130276A1 (es)
SG (1) SG186070A1 (es)
TN (1) TN2012000562A1 (es)
TW (1) TW201204378A (es)
UY (1) UY33465A (es)
WO (1) WO2011162413A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201618783A (zh) 2014-08-07 2016-06-01 艾森塔製藥公司 以布魯頓(Bruton)氏酪胺酸激酶(BTK)佔據和BTK再合成速率為基礎之治療癌症、免疫和自體免疫疾病及發炎性疾病之方法
MA46353A (fr) 2016-09-30 2019-08-07 Myovant Sciences Gmbh Méthodes de traitement de l'infertilité féminine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9211268D0 (en) * 1992-05-28 1992-07-15 Ici Plc Salts of basic peptides with carboxyterminated polyesters
FR2693905B1 (fr) * 1992-07-27 1994-09-02 Rhone Merieux Procédé de préparation de microsphères pour la libération prolongée de l'hormone LHRH et ses analogues, microsphères et formulations obtenues.
AR023940A1 (es) * 2000-05-03 2002-09-04 Eriochem Sa Procedimiento para la produccion de microcapsulas de liberacion prolongada de peptidos solubles en agua
JP5046447B2 (ja) * 2000-08-07 2012-10-10 和光純薬工業株式会社 乳酸重合体及びその製造方法
WO2002085399A1 (en) * 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Peptide-containing preparations
JP2003002841A (ja) * 2001-04-20 2003-01-08 Takeda Chem Ind Ltd ペプチド含有製剤
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
TWI386417B (zh) * 2005-12-22 2013-02-21 Takeda Pharmaceutical 轉移抑素衍生物及其用途
UA97236C2 (en) * 2005-12-22 2012-01-25 Такеда Фармасьютикал Компани Лимитед Metastin derivatives and use thereof
US8404643B2 (en) * 2005-12-22 2013-03-26 Takeda Pharmaceutical Company Limited Metastin derivatives and use thereof
TWI404726B (zh) * 2006-10-25 2013-08-11 Takeda Pharmaceutical 腫瘤轉移抑制素衍生物及其用途
CN101528772B (zh) * 2006-10-25 2013-03-13 武田药品工业株式会社 Metastin衍生物及其用途
MY148370A (en) * 2006-12-18 2013-04-15 Takeda Pharmaceutical Sustained-release composition and method for producing the same
US20110118172A1 (en) * 2008-04-24 2011-05-19 Takeda Pharmaceutical Company Limited Metastin derivative and use thereof
CA2748517A1 (en) * 2008-12-29 2010-07-08 Takeda Pharmaceutical Company Limited Prophylactic/therapeutic agent for cancer
ES2434315T3 (es) * 2009-12-22 2013-12-16 Takeda Pharmaceutical Company Limited Formulación de liberación sostenida

Also Published As

Publication number Publication date
EA021663B1 (ru) 2015-08-31
CA2802209A1 (en) 2011-12-29
TW201204378A (en) 2012-02-01
MA34321B1 (fr) 2013-06-01
CN103025343A (zh) 2013-04-03
BR112012032544A2 (pt) 2016-10-11
KR20130097088A (ko) 2013-09-02
CR20120604A (es) 2013-03-21
TN2012000562A1 (en) 2014-04-01
MX2012014265A (es) 2013-01-18
US20130210742A1 (en) 2013-08-15
EA201291303A1 (ru) 2013-04-30
EP2585091B1 (en) 2014-09-10
ES2513569T3 (es) 2014-10-27
ECSP12012350A (es) 2014-02-28
WO2011162413A1 (en) 2011-12-29
CL2012003645A1 (es) 2013-04-05
CA2802209C (en) 2019-12-31
US20180243422A1 (en) 2018-08-30
DOP2012000304A (es) 2013-01-31
SG186070A1 (en) 2013-01-30
EP2585091A1 (en) 2013-05-01
AU2011270093A1 (en) 2013-01-10
JP2013530926A (ja) 2013-08-01
AR081980A1 (es) 2012-10-31
UY33465A (es) 2012-01-31
CN103025343B (zh) 2015-03-25
IL223266A0 (en) 2013-02-03
JP5838173B2 (ja) 2016-01-06

Similar Documents

Publication Publication Date Title
IN2014MN02106A (es)
NZ739760A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
MD4736B1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
UA114906C2 (uk) Гетероциклільні сполуки як інгібітори мек
CO6491065A2 (es) Formulación farmacéutica
PE20141152A1 (es) Triterpenoides c-17 y c-3 modificados con actividad inhibidora de la maduracion del virus de inmunodeficiencia humana
MX339149B (es) Inhibidores de replicacion del virus de influenza.
EA201390198A1 (ru) Гетероциклическое соединение
EA201592255A1 (ru) Производные пиразолопирролидин-4-она в качестве ингибиторов вет и их применение при лечении заболевания
EA201391525A1 (ru) Гликозидные производные и их применение для лечения диабета
PH12015501752B1 (en) Substituted bisphenyl butanoic phosphonic acid derivatives as nep inhibitors
PH12015502802A1 (en) Formulation comprising a hypolipidemic agent
BR112012017994B8 (pt) composição líquida, uso de uma composição líquida, e, métodos para preparar uma composição líquida e para tratamento de um distúrbio
CU20140005A7 (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
EP4327886A3 (en) Pyrimido- pyridazinone compounds and use thereof
UY30871A1 (es) Uso derivados de acido de piranona sustituidos para producir medicamentos para tratar el sindrome metabolico.
CL2014003012A1 (es) Formulación en capsulas que comprende al menos un compuesto de formula (i), solubilizado; metodo de administracion de la formulacion; uso para tratar una infeccion por el virus de la hepatitis c.
TR201902057T4 (tr) Tetrasiklin bileşikleri.
AR080204A1 (es) Procesos para preparar ciclopropilamidas e intermedios asociados con estas
PE20130276A1 (es) Formulacion de liberacion sostenida
BR112015006243A2 (pt) agentes antibacterianos de fenicol
MX2015010434A (es) Derivados de acido bisfenil-butanoico sustituido como inhibidores de la endopeptidasa neutra (nep), con una mayor eficacia in vivo.
MX2014011520A (es) Administracion de eritoran o sales farmaceuticamente aceptables del mismo para tratar infecciones para ortomixovirus.
PE20121481A1 (es) Formulacion de liberacion sostenida
CY1120482T1 (el) Μεθοδος συνθεσης 3,4-διμεθοξυδικυκλο[4.2.0]οκτα-1,3,5-τριενο-7-καρβονιτριλιου και εφαρμογη στη συνθεση της ιβαμπραδινης και των αλατων προσθηκης αυτης με ενα φαρμακευτικως αποδεκτο οξy

Legal Events

Date Code Title Description
FD Application declared void or lapsed